Clinical Pharmacology and Cardiovascular Safety of Naproxen

Figures

• 

  Fig. 1. Non-steroidal anti-inflammatory drug cyclooxygenase selectivity and half-life. Adapted from Goodman and Gilman [19]. COX cyclooxygenase, NSAID non-steroidal anti-inflammatory drug

• 

  Fig. 2. Odds ratios and 95 % confidence intervals for cardiovascular death based on non-steroidal anti-inflammatory drug (NSAID) dose. Odds ratios for cardiovascular death (composite endpoint of death or myocardial infarction) in association with NSAID exposure Data from Fosbøl et al. [98]

• 

  Fig. 3. Annual absolute effects per 1000 of cyclooxygenase-2-selective non-steroidal anti-inflammatory drugs (NSAIDs) and traditional tNSAIDs at different baseline risks of major vascular events. For each drug category, the predicted annual absolute risks of major vascular events (±1 standard error) are shown for patients with predicted risk of 2.0 % (high risk) or 0.5 % (low risk) per annum of a major vascular event. Data from the CNT meta-analysis [68]. SE standard error

• 

  Fig. 4. Rate ratios and 95 % confidence intervals for major vascular events due to non-steroidal anti-inflammatory drugs. Data from the CNT meta-analysis [68] and McGettigan and Henry [67] meta-analysis

• 

  Fig. 5. Rate ratios and 95 % confidence intervals for myocardial infarction or coronary heart disease death due to non-steroidal anti-inflammatory drug. Data from the CNT meta-analysis [68]

• 

  Fig. 6. Rate ratios and 95 % confidence intervals for hospitalizations for congestive heart failure due to non-steroidal anti-inflammatory drugs. Data from the CNT meta-analysis [68]